Implant for intraocular drug delivery
First Claim
1. An implant for intraocular drug delivery for the treatment of inflammatory or degenerative eye diseases, comprising:
- a. a body portion having a first end portion, a second, opposite end portion, an outer surface, an interior surface, and a length L defined between the first end portion and the second end portion, wherein the body portion defines a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion; and
b. a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent, wherein when the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.
2 Assignments
0 Petitions
Accused Products
Abstract
An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion, and a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent. When the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.
143 Citations
61 Claims
-
1. An implant for intraocular drug delivery for the treatment of inflammatory or degenerative eye diseases, comprising:
-
a. a body portion having a first end portion, a second, opposite end portion, an outer surface, an interior surface, and a length L defined between the first end portion and the second end portion, wherein the body portion defines a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion; and
b. a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent, wherein when the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. An implant for intraocular drug delivery, comprising:
-
a. a body portion having an outer surface and an interior surface, wherein the interior surface defines a cavity with at least one opening; and
b. an effective amount of at least one therapeutic compound or agent received in the cavity, wherein when the implant is implanted in the eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through the at least one opening over an extended period of time. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
34. An eye implant, comprising:
-
a. a first material; and
b. a second material containing an effective amount of at least one therapeutic compound or agent, wherein the first material and the second material are arranged to form a solid, and when the eye implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is releasable to the environment of the implant over an extended period of time. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. A method of treating inflammatory or degenerative diseases in or around the eye, comprising the steps of:
-
a. providing an eye implant having;
(i). a first material; and
(ii). a second material containing an effective amount of at least one therapeutic compound or agent,
wherein the first material and the second material are arranged to form a solid; and
b. implanting the eye implant in an eye of a living subject, wherein the effective amount of at least one therapeutic compound is releasable to the environment of the eye implant over an extended period of time. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60, 61)
-
Specification